CStone Pharmaceuticals Management
Management criteria checks 3/4
CStone Pharmaceuticals' CEO is Jason Yang, appointed in Aug 2022, has a tenure of 2.42 years. total yearly compensation is CN¥57.81M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 1.3% of the company’s shares, worth €4.47M. The average tenure of the management team and the board of directors is 2.2 years and 5.7 years respectively.
Key information
Jason Yang
Chief executive officer
CN¥57.8m
Total compensation
| CEO salary percentage | 8.3% |
| CEO tenure | 2.4yrs |
| CEO ownership | 1.3% |
| Management average tenure | 2.2yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥142m |
| Mar 31 2024 | n/a | n/a | -CN¥255m |
| Dec 31 2023 | CN¥58m | CN¥5m | -CN¥367m |
| Sep 30 2023 | n/a | n/a | -CN¥559m |
| Jun 30 2023 | n/a | n/a | -CN¥750m |
| Mar 31 2023 | n/a | n/a | -CN¥827m |
| Dec 31 2022 | CN¥62m | CN¥3m | -CN¥903m |
Compensation vs Market: Jason's total compensation ($USD7.89M) is above average for companies of similar size in the German market ($USD973.18K).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
CEO
Jason Yang (60 yo)
2.4yrs
Tenure
CN¥57,808,000
Compensation
Dr. Jianxin Yang, M.D., Ph D., also known as Jason, serves as President of R&D of CStone Pharmaceuticals since 2024 and was its Senior Vice President and Chief Medical Officer December 2016 until 2024. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President of R&D and Executive Director | 2.4yrs | CN¥57.81m | 1.3% € 4.5m | |
| CFO & Joint Company Secretary | 2yrs | no data | no data | |
| Senior VP & Chief Operating Officer | less than a year | no data | no data | |
| Senior VP & Chief Scientific Officer | no data | no data | no data | |
| Chief Commercial & Strategic Officer | 3.7yrs | no data | no data | |
| Senior Vice President of Product Development | 3.7yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
2.2yrs
Average Tenure
49yo
Average Age
Experienced Management: PH4's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President of R&D and Executive Director | no data | CN¥57.81m | 1.3% € 4.5m | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Independent Non-Executive Director | 5.9yrs | CN¥282.00k | no data | |
| Non-Executive Director | 4.2yrs | no data | no data | |
| Independent Non-Executive Director | 5.9yrs | CN¥711.00k | no data | |
| Non Executive Director | 3.1yrs | CN¥415.00k | no data | |
| Member of Scientific Advisory Board | 5.6yrs | no data | no data | |
| Independent Non-Executive Director | 5.9yrs | CN¥282.00k | no data | |
| Non-Executive Chairman | 9.1yrs | no data | no data | |
| Non-Executive Director | 3.5yrs | no data | 0.072% € 248.6k |
5.7yrs
Average Tenure
60.5yo
Average Age
Experienced Board: PH4's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 15:28 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CStone Pharmaceuticals is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| Ling Wang | J.P. Morgan |
| Sean Wu | Morgan Stanley |